Race Oncology signs distribution deal with BL&H Korea
Monday, 03 April, 2017
Australian-listed pharmaceutical company Race Oncology has signed an exclusive licence agreement with BL&H Korea for the sale of Bisantrene, an agent for the treatment of acute myelogenous leukaemia, under a named patient program (NPP).
The NPP mechanism in South Korea allows for pre-approval access and sales of medicines in response to requests by physicians on behalf of specific, or “named”, patients.
“We are very excited to bring Bisantrene to the South Korean market. Bisantrene represents a unique commercial opportunity for our company because of its clinical benefits for AML patients,” said DC Roh, president, BL&H.
Race Oncology’s CEO Peter Molloy said the deal signals the commercial potential for Bisantrene NPP partnerships in Asia and anticipated NPP launches in Europe commencing later this year.
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
